Nephrectomy

Video-based evaluation of robot-assisted partial nephrectomy may be an important step to assess surgical skill and improve patient care, according to recently published data.

Donor nephrectomy in living kidney donors aged 70 years or older is safe and does not significantly impact eGFR or the risk of end-stage renal disease, recently published data show.

NASHVILLE, Tenn. — A fully automated artificial intelligence approach predicted post-nephrectomy glomerular filtration rate with comparable accuracy as validated clinical prediction models, according to study results.

NASHVILLE, Tenn. — Adjuvant pembrolizumab appeared well tolerated among patients with high-risk renal cell carcinoma after nephrectomy, according to study results.

NASHVILLE, Tenn. — Diabetes appeared linked to shorter survival among patients who underwent nephrectomy for renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium: North America.

In this video, Farshid Sadeghi, MD, discussed data presented on renal cell carcinoma at American Urological Association Annual Meeting.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, gives a summary of a subgroup analysis of the KEYNOTE-564 study he presented at the annual ASCO Genitourinary Cancers Symposium.

CHICAGO — In renal cell carcinoma, adjuvant everolimus improved recurrence-free survival after nephrectomy but narrowly missed the benchmark for statistical significance, according to final results from the phase 3 EVEREST study.

Living kidney donor surgery is safe and low risk for most patients, according to a 20-year study conducted by the Mayo Clinic.

In this video, Mark W. Ball, MD, discusses updates from the KEYNOTE-564 study on the use of adjuvant pembrolizumab in certain patients with renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.